IO102-IO103 clinical trials

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

This study looks at a new combination treatment for advanced melanoma, a type of skin cancer. It compares giving a new drug called IO102-IO103 alongside an existing drug, pembrolizumab, with giving pembrolizumab alone. The aim is to see if the combination helps patients live longer without their cancer getting worse.